Skip to main content
SpringerLink
Log in

Therapeutic node dissections in malignant melanoma

  • Surgical Oncology Forum
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background: Therapeutic lymphadenectomies involve the dissection and removal of clinically enlarged, histologically positive nodes at the regional nodal basin, in the absence of detectable distant disease.

Methods: The literature dealing with therapeutic lymphadenectomies in malignant melanoma was reviewed.

Results: The rate of wound complications varies with the particular nodal basin. The 5-year survival varies from 19% to 38%, with an average of 26%. Survival is affected primarily by the number of histologically positive nodes and extracapsular spread, and secondarily by the extent of disease at the various levels of the nodal basin, fixation of the nodes, and, probably, the preceding disease-free interval. Prognostic parameters of the primary lesion, e.g., thickness, ulceration, and location, also may have an effect on survival. The rate of local recurrence at the nodal basin after lymphadenectomy has varied from 0.8% to 52%. Adjuvant therapy with interferon alfa-2b has improved the 5-year disease-free survival from 26% to 37%.

Conclusions: Therapeutic node dissections in melanoma provide an appreciable 5-year survival rate, which is further augmented by adjuvant therapy. Many series report a significant rate of local recurrence at the nodal basin following therapeutic dissection. Complete lymphadenectomy reduces the rate of local failure with its attendant morbidity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection in stage I melanoma of the limbs.N Engl J Med 1977;297:627–30.

    CAS  PubMed  Google Scholar 

  2. Sim FH, Taylor WF, Ivins JC, et al. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma.Cancer 1978;41:948–56.

    CAS  PubMed  Google Scholar 

  3. Balch CM, Soong S-J, Bartolucci AA, Urist MM, Karakousis CP, et al. Efficacy of an elective regional lymph node dissection of 1- to 4-mm thick melanomas for patients 60 years of age and younger.Ann Surg 1996;224:255–66.

    Article  CAS  PubMed  Google Scholar 

  4. Morton DL, Wen D-R, Wong JH, et al. Technical details of intra-operative mapping for early stage melanoma.Arch Surg 1992;127:392–9.

    CAS  PubMed  Google Scholar 

  5. Karakousis CP, Balch CM, Urist MM, Ross MI, Smith TJ, Bartolucci AA. Local recurrence in malignant melanoma: long-term results of the multi-institutional randomized surgical trial.Ann Surg Oncol 1996;3:446–52.

    CAS  PubMed  Google Scholar 

  6. Konstadoulakis M, Karakousis CP, Walsh D, Ricaniadis N. Survival of patients with stage IA malignant melanoma.Surg Oncol 1995;4:101–4.

    CAS  PubMed  Google Scholar 

  7. Wong JH, Cagle LA, Morton DL. Surgical treatment of lymph nodes with metastatic melanoma from unknown primary site.Arch Surg 1987;122:1380–3.

    CAS  PubMed  Google Scholar 

  8. Karakousis CP, Emrich LJ, Driscoll DL, Rao U. Survival after groin dissection for malignant melanoma.Surgery 1991;109:119–26.

    CAS  PubMed  Google Scholar 

  9. Shaw JHF, Koea J. Morbidity of lymphadenectomy for melanoma.Surg Oncol Clin North Am 1992;1:195–203.

    Google Scholar 

  10. Kane M, McClay E, Bellet RE. Frequency of occult residual melanoma after excision of a clinically positive regional lymph node.Ann Surg 1987;205:88–9.

    CAS  PubMed  Google Scholar 

  11. Karakousis CP, Rizos S, Driscoll DL. Residual nodal disease after excisional biopsy of a palpable, positive node in melanoma.Am J Surg 1994;168:69–70.

    Article  CAS  PubMed  Google Scholar 

  12. Kuvshinoff BW, Kurtz C, Coit DG. Computed tomography in evaluation of patients with stage III melanoma.Ann Surg Oncol 1997;4:252–8.

    Article  CAS  PubMed  Google Scholar 

  13. Buzaid AC, Tinoco L, Ross MI, Legha SS, Benjamin RS. Role of computed tomography in the staging of patients with loco-regional metastases of melanoma.J Clin Oncol 1995;13:2104–8.

    CAS  PubMed  Google Scholar 

  14. Karakousis CP, Velez A, Driscoll DL, Takita H. Metastasectomy in malignant melanoma.Surgery 1994;115:295–302.

    CAS  PubMed  Google Scholar 

  15. O'Brien CJ, Fisher SR. Neck dissection and parotidectomy. In: Balch CM, Houghton AN, Sober AJ, Soong S-j, eds.Cutaneous Melanoma. 3rd ed. St. Louis: Quality Medical Publishing, 1998:245–57.

    Google Scholar 

  16. O'Brien CJ, Peterson-Schaefer K, Ruark D, Coates AS, Menzie SJ, Harrison RI. Radical, modified and selective neck dissection for cutaneous malignant melanoma.Head Neck 1995;17:232–41.

    PubMed  Google Scholar 

  17. Mansfield PF, Ames FC, Balch CM. Axillary lymph node dissection. In: Balch CM, Houghton AN, Sober AJ, Soong S-j, eds.Cutaneous Melanoma. 3rd ed. St. Louis: Quality Medical Publishing, 1998:259–68.

    Google Scholar 

  18. Balch CM. Axillary lymph node dissection: differences in goals and techniques when treating melanoma and breast cancer.Surgery 1990;108:118–9.

    CAS  PubMed  Google Scholar 

  19. Coit DG. Extent of groin dissection for melanoma.Surg Oncol Clin North Am 1992;1:271–80.

    Google Scholar 

  20. Karakousis CP. The technique of popliteal lymph node dissection.Surg Gynecol Obstet 1980;151:420–3.

    CAS  PubMed  Google Scholar 

  21. Coit DG, Peters M, Brennan MF. A prospective randomized trial of perioperative Cefazolin treatment in axillary and groin dissection.Arch Surg 1991;126:1366–72.

    CAS  PubMed  Google Scholar 

  22. Urist MM, Maddox WA, Kennedy JE, Balch CM. Patient risk factors and surgical morbidity after regional lymphadenectomy in 204 melanoma patients.Cancer 1983;51:2152–6.

    CAS  PubMed  Google Scholar 

  23. Stringer SP, Cassisi NJ. Radical and modified neck dissection. In: Bland K, Karakousis CP, Copeland E, eds.Atlas of Surgical Oncology. Philadelphia: WB Saunders, 1995;165–80.

    Google Scholar 

  24. Karakousis CP, Goumas W, Rao U, Driscoll DL. Axillary node dissection in malignant melanoma.Am J Surg 1991;162:202–7.

    Article  CAS  PubMed  Google Scholar 

  25. Karakousis CP, Hena MA, Emrich LJ, Driscoll DL. Axillary node dissection in malignant melanoma: Results and complications.Surg 1990;108:10–7.

    CAS  Google Scholar 

  26. Karakousis CP, Driscoll DL, Rose B, Walsh DL. Groin dissection in malignant melanoma.Ann Surg Oncol 1994;1:271–7.

    Article  CAS  PubMed  Google Scholar 

  27. Beitsch P, Balch C. Operative morbidity and risk factor assessment in melanoma patients undergoing inguinal lymph node dissection.Am J Surg 1992;164:462–5.

    CAS  PubMed  Google Scholar 

  28. Rapaport DP, Stadelman WK, Reintgen DS. Inguinal lymphadenectomy. In: Balch CM, Houghton AN, Sober AJ, Soong S-j, eds.Cutaneous Melanoma. 3rd ed. St. Louis: Quality Medical Publishing, 1998:269–80.

    Google Scholar 

  29. Stadelmann WK, Rapaport DP, Soong S-j, Reintgen DS, Buzaid AC, Balch CM. Prognostic clinical and pathologic features. In: Balch CM, Houghton AN, Sober AJ, Soong S-j, eds.Cutaneous Melanoma. 3rd ed. St. Louis: Quality Medical Publishing, 1998:11–35.

    Google Scholar 

  30. Tillman DM, Aitchison T, Watt DC, Mackie RM. Stage II melanoma in the West of Scotland, 1976–1985: prognostic factors for survival.Eur J Cancer 1991;27:870–6.

    CAS  PubMed  Google Scholar 

  31. Buzaid AC, Ross MI, Soong S-j. Classification and staging. In: Balch CM, Houghton AN, Sober AJ, Soong S-j, eds.Cutaneous Melanoma. 3rd ed. St. Louis: Quality Medical Publishing, 1998:37–47.

    Google Scholar 

  32. Buzaid AC, Tinoco LA, Jendiroba D, et al. Prognostic value of size of lymph node metastases in patients with cutaneous melanoma.J Clin Oncol 1995;13:2361–8.

    CAS  PubMed  Google Scholar 

  33. Morton DL, Wanek L, Nizze JA, Elashoff RM, Wong JH. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic.Ann Surg 1991;214:491–9.

    CAS  PubMed  Google Scholar 

  34. Bevilacqua RG, Coit DG, Rogatko A, Younes RN, Brennan MF. Axillary dissection in melanoma. Prognostic variables in node-positive patients.Ann Surg 1990;212:125–31.

    CAS  PubMed  Google Scholar 

  35. Barth RJ Jr, Venzon DJ, Baker AR. The prognosis of melanoma patients with metastases to two or more lymph node areas.Ann Surg 1991;214:125–30.

    PubMed  Google Scholar 

  36. Dale PS, Foshag LJ, Wanek LA, Morton DL. Metastasis of primary melanoma to two separate lymph node basins: prognostic significance.Ann Surg Oncol 1997;4:13–8.

    CAS  PubMed  Google Scholar 

  37. O'Brien CJ, Peterson-Schaefer K, Stevens GN, et al. Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma.Head Neck 1997;19:589–94.

    Article  PubMed  Google Scholar 

  38. Coit DG. Prognostic factors in patients with melanoma metastatic to regional nodes.Surg Oncol Clin North Am 1992;1:281–95.

    Google Scholar 

  39. Warso MA, Das Gupta TK. Melanoma recurrence in a previously dissected nodal basin.Arch Surg 1994;129:252–5.

    CAS  PubMed  Google Scholar 

  40. Kretschmer L, Lautenschlager C, Preusser KP, Fiedler H, Hetschkol. Axillary recurrence after lymph node excision in malignant melanoma.Langenbecks Arch fur Chirurgie 1993;378:4–11.

    CAS  Google Scholar 

  41. Kretschmer L, Lautenschlager C, Preusser KP, Ffiedler H. Inguinal recurrence after therapeutic lymphadenectomy in malignant melanoma.Langenbecks Arch fur Chirurgie 1993;378:211–6.

    CAS  Google Scholar 

  42. Byers RM. The role of modified neck dissection in the treatment of cutaneous melanoma of the head and neck.Arch Surg 1986;12:1338–41.

    Google Scholar 

  43. Monsour PD, Sause WT, Avent JM, Noyes RD. Local control following therapeutic nodal dissection for melanoma.J Surg Oncol 1993;54:18–22.

    CAS  PubMed  Google Scholar 

  44. Karakousis CP, Driscoll DL. Positive deep nodes in the groin and survival in malignant melanoma.Am J Surg 1996;171:421–2.

    Article  CAS  PubMed  Google Scholar 

  45. McCarthy JH, Haagensen CK-D, Herter FP. The role of groin dissection in the management of melanoma of the lower extremity.Ann Surg 1974;179:156–9.

    CAS  PubMed  Google Scholar 

  46. Cohen MH, Schour L, Felix EL, et al. Staging laparotomy in the treatment of metastatic melanoma of the lower extremities.Ann Surg 1976;182:710–4.

    Google Scholar 

  47. Singletary SE, Schallenberger R, Guinee VF. Surgical management of groin nodal metastases from primary melanoma of the lower extremity.Surg Gynecol Obstet 1992;174:195–200.

    CAS  PubMed  Google Scholar 

  48. Coit DG, Brennan MF. Extent of lymph node dissection in melanoma of the trunk or lower extremity.Arch Surg 1989;124:162–6.

    CAS  PubMed  Google Scholar 

  49. Fortner JG, Booher RJ, Pack GT. Results of groin dissection for malignant melanoma in 220 patients.Surgery 1964;55:485–94.

    CAS  PubMed  Google Scholar 

  50. Finck SJ, Giuliano AE, Mann D, Morton DL. Results of ilioinguinal dissection for stage II melanoma.Ann Surg 1982;196:180–6.

    CAS  PubMed  Google Scholar 

  51. Jonk A, Kroon BB, Rumke P, van der Esch EP, Hart AA. Results of radical dissection of the groin in patients with stage II melanoma and histologically proved metastases of the iliac or obturator nodes, or both.Surg Gynecol Obstet 1988;167:28–32.

    CAS  PubMed  Google Scholar 

  52. Kissin MW, Simpson DA, Easton D, White H, Westbury G. Prognostic factors related to survival and groin recurrence following therapeutic lymph node dissection for lower limb malignant melanoma.Br J Surg 1987;74:1023–6.

    CAS  PubMed  Google Scholar 

  53. McNeer G, Das Gupta TK. Prognosis in malignant melanoma.Surgery 1964;56:512–8.

    Google Scholar 

  54. Cohen MH, Ketcham AS, Felix EL, et al. Prognostic factors in patients undergoing lymphadenectomy for malignant melanoma.Ann Surg 1977;186:635–42.

    CAS  PubMed  Google Scholar 

  55. Das Gupta TK. Results of treatment of 269 patients with primary cutaneous melanoma: a five-year prospective study.Ann Surg 1977;186:201–9.

    Google Scholar 

  56. Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma, III: prognostic factors in melanoma patients with lymph node metastases (stage II).Ann Surg 1981;193:377–88.

    CAS  PubMed  Google Scholar 

  57. Callery C, Cochran AJ, Roe DJ, et al. Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes.Ann Surg 1982;196:69–75.

    CAS  PubMed  Google Scholar 

  58. Roses DF, Provet JA, Harris MN, Gumport SL, Dubin N. Prognosis of patients with pathologic stage II cutaneous malignant melanoma.Ann Surg 1985;201:103–7.

    CAS  PubMed  Google Scholar 

  59. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684.J Clin Oncol 1996;14:7–17.

    CAS  PubMed  Google Scholar 

  60. Burmeister BH, Smithers BM, Poulsen M, McLeod GR, Bryant G, Tripcong L, Thorpe C. Radiation therapy for nodal disease in malignant melanoma.World J Surg 1995;19:369–71.

    Article  CAS  PubMed  Google Scholar 

  61. Strom EA, Ross MI. Adjuvant radiation therapy after axillary lymphadenectomy for metastatic melanoma: toxicity and local control.Ann Surg Oncol 1995;2:445–9.

    Article  CAS  PubMed  Google Scholar 

  62. Petrek JA, Blackwood MM. Axillary dissection: current practice and technique.Curr Probl Surg 1995;32:257–323.

    CAS  PubMed  Google Scholar 

  63. Morton DL, Hoon DSB, Nizza JA, et al. Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma.Ann N Y Acad Sci 1993;690:120–34.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. From the Department of Surgery, State University of New York at Buffalo, Millard Fillmore Health System, Buffalo, New York

    Constantine P. Karakousis MD, PhD

Authors
  1. Constantine P. Karakousis MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Karakousis, C.P. Therapeutic node dissections in malignant melanoma. Annals of Surgical Oncology 5, 473–482 (1998). https://doi.org/10.1007/BF02303638

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02303638

Key Words

Search

Navigation